Lack of pharmacokinetic interaction between derazantinib and naringin in rats

References

• Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, et al. 2020. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 21(5):671–684.
   PubMed Web of Science ®Google Scholar
• Aitcheson G, Mahipal A, John BV. 2021. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]? Expert Opin Investig Drugs. 30(4):463–477.
   PubMed Web of Science ®Google Scholar
• Bai Y, Peng W, Yang C, Zou W, Liu M, Wu H, Fan L, Li P, Zeng X, Su W. 2020. Pharmacokinetics and metabolism of naringin and active metabolite naringenin in rats, dogs, humans, and the differences between species. Front Pharmacol. 11:364.
   PubMed Web of Science ®Google Scholar
• Banjerdpongchai R, Wudtiwai B, Khawon P. 2016. Induction of human hepatocellular carcinoma HepG2 cell spoptosis by naringin. Asian Pac J Cancer Prev. 17:3289–3294.
   PubMedGoogle Scholar
• Booth B, Arnold ME, DeSilva B, Amaravadi L, Dudal S, Fluhler E, Gorovits B, Haidar SH, Kadavil J, Lowes S, et al. 2015. Workshop report: crystal City V–quantitative bioanalytical method validation and implementation: the 2013 revised FDA guidance. Aaps J. 17(2):277–288.
   PubMed Web of Science ®Google Scholar
• Braun S, McSheehy P, Litherland K, McKernan P, Forster-Gross N, Bachmann F, El-Shemerly M, Dimova-Dobreva M, Polyakova I, Hackl M, et al. 2021. Derazantinib: an investigational drug for the treatment of cholangiocarcinoma. Expert Opin Investig Drugs. 30:1071–1080.
   PubMed Web of Science ®Google Scholar
• Chtourou Y, Aouey B, Aroui S, Kebieche M, Fetoui H. 2016. Anti-apoptotic and anti-inflammatory effects of naringin on cisplatin-induced renal injury in the rat. Chem Biol Interact. 243:1–9.
   PubMed Web of Science ®Google Scholar
• Elsawy H, Algefare AI, Alfwuaires M, Khalil M, Elmenshawy OM, Sedky A, Abdel-Moneim AM. 2020. Naringin alleviates methotrexate-induced liver injury in male albino rats and enhances its antitumor efficacy in HepG2 cells. Biosci Rep. 40:BSR20193686.
   PubMed Web of Science ®Google Scholar
• Gourd E. 2019. Derazantinib for intrahepatic cholangiocarcinoma. Lancet Oncol. 20(1):e11.
   PubMed Web of Science ®Google Scholar
• Hall TG, Yu Y, Eathiraj S, Wang Y, Savage RE, Lapierre JM, Schwartz B, Abbadessa G. 2016. Preclinical activity of ARQ 087, a novel inhibitor targeting FGFR dysregulation. PLoS One. 11(9):e0162594.
   PubMed Web of Science ®Google Scholar
• Jain A, Borad MJ, Kelley RK, Wang Y, Abdel-Wahab R, Meric-Bernstam F, Baggerly KA, Kaseb AO, Al-Shamsi HO, Ahn DH, et al. 2018. Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype. J Clin Oncol Precis Oncol. 2:1–12.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Bridgewater J, Gores GJ, Zhu AX. 2020. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 72:353–363.
   PubMed Web of Science ®Google Scholar
• King G, Javle M. 2021. FGFR Inhibitors: clinical activity and development in the treatment of cholangiocarcinoma. Curr Oncol Rep. 23:108.
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Sibaud V, Anadkat MJ, Kaffenberger B, Leventhal J, Guindon K, Abou-Alfa G. 2021. Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines. Oncologist. 26(2):e316–e326.
   PubMed Web of Science ®Google Scholar
• Lim SC, Choi JS. 2006. Effects of naringin on the pharmacokinetics of intravenous paclitaxel in rats. Biopharm Drug Dispos. 27:443–447.
   PubMed Web of Science ®Google Scholar
• Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, Kemeny NE, O'Reilly EM, El-Dika I, Jarnagin WR, et al. 2018. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 24:4154–4161.
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, Masi G, Rimassa L, Personeni N, Braiteh F, et al. 2019. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 120(2):165–171.
   PubMed Web of Science ®Google Scholar
• Memariani Z, Abbas SQ, Ul Hassan SS, Ahmadi A, Chabra A. 2021. Naringin and naringenin as anticancer agents and adjuvants in cancer combination therapy: efficacy and molecular mechanisms of action, a comprehensive narrative review. Pharmacol Res. 171:105264.
   PubMed Web of Science ®Google Scholar
• Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. 2010. Mechanisms of cisplatin nephrotoxicity. Toxins. 2:2490–2518.
   PubMed Web of Science ®Google Scholar
• Papadopoulos KP, El-Rayes BF, Tolcher AW, Patnaik A, Rasco DW, Harvey RD, LoRusso PM, Sachdev JC, Abbadessa G, Savage RE, et al. 2017. A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours. Br J Cancer. 117:1592–1599.
   PubMed Web of Science ®Google Scholar
• Raggi C, Fiaccadori K, Pastore M, Correnti M, Piombanti B, Forti E, Navari N, Abbadessa G, Hall T, Destro A, et al. 2019. Antitumor activity of a novel fibroblast growth factor receptor inhibitor for intrahepatic cholangiocarcinoma. Am J Pathol. 189:2090–2101.
   PubMed Web of Science ®Google Scholar
• Rizvi S, Gores GJ. 2013. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterol. 145(6):1215–1229.
   PubMed Web of Science ®Google Scholar
• Silverman IM, Hollebecque A, Friboulet L, Owens S, Newton RC, Zhen H, Feliz L, Zecchetto C, Melisi D, Burn TC. 2021. Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib. Cancer Discov. 11:326–339.
   PubMed Web of Science ®Google Scholar
• Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH. 2003. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol. 14:1–10.
   PubMed Web of Science ®Google Scholar
• Yen HR, Liu CJ, Yeh CC. 2015. Naringenin suppresses TPA-induced tumor invasion by suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells. Chem Biol Interact. 235:1–9.
   PubMed Web of Science ®Google Scholar